Robinson Bradshaw

Month: February 2010

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: RT @fredcobio: LavaAmp in @WIRED The First and Last Meeting of Everyone with a Fully […]

Personal Genomics in the News: Desmond Tutu and the GET Conference

It’s been a busy twenty-four hours in the world of personal genomics. Yesterday, as announced in the journal Nature, the number of individuals who have had their genomes sequenced and made publicly available increased by two. Archbishop Desmond Tutu and !Gubi, a tribal elder from a Bushman (or Khoisan) community in Namibia, joined the ranks […]

Problems with Problem Employees

Fresh from a top biochemistry Ph.D. program, Beth was your fifth employee. Her technical expertise and ability to charm investors, lenders and prospective customers made her the obvious choice when, as the company burgeoned, you decided to formalize a roster of senior officers. As Executive Vice President for Biotechnology, Beth has since had a hand […]

GLR Update: Australia Tackles Disclosure of Genetic Information without Consent

Last fall, the Genomics Law Report reviewed new medical confidentiality guidance from the U.K. General Medical Council (GMC) and wondered whether the “public interest” was a sufficient justification for the disclosure of patients’ genetic information without their consent. Since that time, Australia’s National Health and Medical Research Council (NHMRC) has tackled the same issue, publishing new […]

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: RT @jensmccabe: pharma + academia: cross-pollination between Lilly and Harvard? Interesting – http://tinyurl.com/yaecory RT @crossborderbio: […]

Raising Private Capital Redux

Now that you’ve decided to raise private capital, what’s your next move? How do you go about finding and signing up investors for your business? Unfortunately, fundraising is a difficult, frustrating and lengthy process for most entrepreneurs. The path to financing does not end with a strong patented technology, a solid business plan and model, […]

SACGHS Gene Patent Recommendations Still Controversial

The Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) for the Department of Health and Human Services (HHS) convened again on Friday for a snow-shortened session. One of several items on the Committee’s agenda was a report that the GLR has covered several times (see here and here): Gene Patents and Licensing Practices and […]

Weekly Twitter Roundup

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer: RT @DukeIGSP: Myriad’s profits rise. CEO says publicity from gene patent suit has benefited company. […]

Up Next in Gene Patents: Waiting for a Ruling (Again) and SACGHS Meets (Again)

GenomeWeb has a recap of today’s hearing in the Myriad case, including the not-at-all-surprising decision that there was no summary judgment decision issued from the bench. From all accounts the case appears to have been argued along the lines set forward by the parties in their briefs, with no obvious surprises presented by either party […]

Final Words from the Sidelines as Courtroom Arguments Begin in Gene Patent Litigation

Yesterday, on the eve of summary judgment arguments in the Myriad case, The Boston Globe editorialized—strongly—against patenting isolated genes. This is an issue in which the Globe has a natural interest, given the concentration of biotech companies in and around Boston. The Globe’s editorialists may or may not be right on the merits, but they […]